1). How many other CCR5 receptor blockers are in clinical trials for the indications Cytodyn is pursuing, WITHOUT SAEs to boot? I’ll wait.
2). Dr. Bruce Patterson correctly noted the distinction of how the inflammatory process is initiated, they didn’t ‘switch’ anything. But nice try trying to pin some sort of ‘consirscy’ on management. Pathophysiology much?
3). Management sold what was rightfully theirs to sell. They didn’t even HAVE TO put anything back into the company, but they did.
4). It is typical for pre-revenue companies to pay to promote their company. Even big pharma does so with all their pharmaceuticals. I mean, why advertise if a drug works, right? Or are they looking to make more sales too?
5). Don’t really care as long as the message coming from the company is accurate.
6). This is a non-point. He was never convicted. This needs to stop being brought up as it has absolutely NO bearing on Cytodyn.
7). Seems like you’ll have to take that up with Cool Blue Capital. Still doesn’t Co anger the fundamentals of the drug, it’s development, progress or future outcomes.
Next!